California Center For Ketamine Therapy: Secrets Revealed

The FDA’s approval of ketamine for depression hinges on multiphase clinical studies, which are unlikely to happen. Pharmaceutical companies usually pay for clinical trials and can’t make money off a decades-old generic drug. “You can get a few years of exclusivity for a new use, but generally you need more than a few years to recoup the research and development costs of bringing a drug to market,” says Michael Thase, a professor of psychiatry at the University of Pennsylvania who’s consulted for various drug companies developing ketamine-like products.You can get additional information at California Center for Ketamine Therapy – Ketamine Clinic, Los Angeles. Instead, companies are spending millions to develop similar, patentable drugs. According to Bloomberg Business, Janssen is seeking approval for a nasal spray made from esketamine, a variation of the ketamine molecule that’s about 20 percent more potent, says […]